{"gene":"NYX","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2000,"finding":"NYX encodes nyctalopin, a GPI-anchored protein and novel member of the small leucine-rich proteoglycan (SLRP) family; mutations in NYX cause X-linked complete congenital stationary night blindness (CSNB1) with ON-pathway defects, implicating nyctalopin in developing retinal interconnections involving ON-bipolar cells.","method":"Positional cloning, mutation screening in 22 CSNB1 families, sequence analysis identifying 14 different mutations","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — positional cloning with 14 independent mutations across 22 families, replicated in multiple subsequent independent studies","pmids":["11062471"],"is_preprint":false},{"year":2003,"finding":"Human nyctalopin is a cell surface protein; the N-terminal ER signal sequence directs it into the secretory pathway and the C-terminal GPI anchor domain is required for its retention at the plasma membrane. Deletion of the GPI anchor causes accumulation in ER/Golgi and loss from the cell surface. Mouse Nyx also localizes to the cell surface (as speckles), and both require the ER signal sequence for proper intracellular localization. Pathogenic LRR-region mutations do not alter subcellular localization.","method":"Expression of V5-tagged wild-type and mutant domain-deletion constructs in COS-7 and HeLa cells; differential live-cell vs. detergent-extracted immunostaining to distinguish surface from intracellular pools","journal":"Investigative ophthalmology & visual science","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct localization assay with functional domain deletions and mutagenesis in multiple cell lines, single lab but multiple orthogonal methods","pmids":["14507859"],"is_preprint":false},{"year":2003,"finding":"Mouse Nyx (nyctalopin) is expressed specifically in the inner nuclear layer and ganglion cell layer of the retina throughout all stages of postnatal retinal development, consistent with a function in the inner retinal circuitry rather than in photoreceptors.","method":"RNA in situ hybridization and immunohistochemistry with Nyx-specific antibodies in mouse and rat retina; RT-PCR for tissue distribution","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization by in situ hybridization and immunohistochemistry in two species, single lab","pmids":["12714669"],"is_preprint":false},{"year":2004,"finding":"Nyctalopin (NYX) acts principally or exclusively within the ON-pathway at the level of depolarizing (ON) bipolar cells; pharmacological blockade of the ON-pathway in non-human primates with APB fully recreates the ERG abnormalities seen in CSNB1-NYX humans, with no evidence of OFF-pathway involvement.","method":"ERG recordings in genotyped CSNB1-NYX human males combined with intravitreal injection of ON-pathway blocker APB and OFF-pathway blocker PDA in anesthetized primates; comparative sinusoidal and ramp-flicker ERG analysis","journal":"Journal of neurophysiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological epistasis in primate combined with human genotype-confirmed patient data, replicated across multiple stimulation paradigms","pmids":["15331616"],"is_preprint":false},{"year":2001,"finding":"Loss of functional nyctalopin (NYX) abolishes signal transmission through the ON rod bipolar cell (AII amacrine) pathway (slow rod ERG pathway undetectable) but leaves a residual signal via rod-cone gap junctions through the OFF cone pathway (fast rod ERG pathway reduced but present), defining the precise circuit site of nyctalopin action.","method":"15-Hz scotopic flicker ERG with amplitude and phase analysis across a range of flash intensities in 11 NYX-mutation-confirmed CSNB1 patients vs. 22 normal controls","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structured ERG dissection of two rod pathways in genotype-confirmed patients, single lab","pmids":["11581222"],"is_preprint":false},{"year":2006,"finding":"The upstream regulatory sequences of the nyx gene (zebrafish) drive expression in a subset of ON-bipolar cells; live time-lapse imaging of nyx::MYFP transgenic zebrafish showed that bipolar cell axonal terminals develop through filopodial exploration throughout the IPL before concentrating at discrete foci to form large terminal boutons, establishing a trial-and-error mechanism of synaptic targeting.","method":"Transgenic zebrafish expressing membrane-targeted YFP under nyx regulatory sequences; time-lapse confocal and two-photon in vivo imaging of bipolar cell axonal development","journal":"Visual neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vivo live imaging in transgenic vertebrate model, single lab, nyx regulatory sequences validate ON-bipolar cell identity","pmids":["17020638"],"is_preprint":false},{"year":2039,"finding":"A noncoding variant (c.-57G>A) in the 5' UTR/exon 1 of NYX causes aberrant splicing and reduced nyctalopin production, resulting in a milder cCSNB phenotype without high myopia, establishing that noncoding NYX variants can cause disease via a splicing mechanism.","method":"Whole genome sequencing, in silico splicing prediction (SpliceAI, Pangolin), minigene splicing assay","journal":"Acta ophthalmologica","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — minigene assay directly demonstrates aberrant splicing, but single case and single lab","pmids":["41729106"],"is_preprint":false}],"current_model":"Nyctalopin (NYX) is a GPI-anchored, small leucine-rich proteoglycan that is trafficked via the ER/Golgi to the extracellular face of the plasma membrane of ON-bipolar cells in the inner retina, where it is required for signal transmission through the depolarizing (ON) rod bipolar cell pathway; loss of nyctalopin selectively abolishes ON-pathway signaling while leaving residual transmission through rod-cone gap junctions, and mutations in NYX cause X-linked complete congenital stationary night blindness."},"narrative":{"mechanistic_narrative":"Nyctalopin (NYX) is a GPI-anchored small leucine-rich proteoglycan (SLRP) that is required for signal transmission through the depolarizing (ON) bipolar cell pathway of the inner retina, and its loss causes X-linked complete congenital stationary night blindness (CSNB1) [PMID:11062471]. The protein is directed into the secretory pathway by an N-terminal ER signal sequence and retained at the extracellular face of the plasma membrane by a C-terminal GPI anchor; deletion of the GPI anchor traps the protein in the ER/Golgi and removes it from the cell surface, whereas pathogenic LRR-region mutations leave localization intact [PMID:14507859]. Consistent with this circuit role, nyctalopin is expressed in the inner nuclear and ganglion cell layers throughout retinal development rather than in photoreceptors, and zebrafish nyx regulatory sequences mark a subset of ON-bipolar cells [PMID:12714669, PMID:17020638]. Functionally, nyctalopin acts at the level of the depolarizing ON-bipolar cells: pharmacological ON-pathway blockade in primates recapitulates the ERG defect seen in NYX-mutant patients, and loss of nyctalopin abolishes transmission through the ON rod bipolar (AII amacrine) pathway while leaving residual signaling via rod-cone gap junctions feeding the OFF cone pathway [PMID:15331616, PMID:11581222].","teleology":[{"year":2000,"claim":"Established the gene underlying X-linked complete CSNB and identified its product as a novel GPI-anchored SLRP family member, linking a defined molecule to the long-recognized ON-pathway signaling defect.","evidence":"Positional cloning and mutation screening of 22 CSNB1 families identifying 14 distinct mutations","pmids":["11062471"],"confidence":"High","gaps":["Did not define the subcellular localization or trafficking of the protein","No direct identification of binding partners or the molecular signaling step affected"]},{"year":2001,"claim":"Resolved the precise circuit site of nyctalopin action by dissecting which rod pathway is lost, showing the defect is in ON rod bipolar transmission and not in residual rod-cone gap junction routes.","evidence":"15-Hz scotopic flicker ERG amplitude/phase analysis in 11 NYX-confirmed patients vs 22 controls","pmids":["11581222"],"confidence":"Medium","gaps":["ERG phenotyping does not reveal the molecular partners or mechanism at the bipolar cell synapse","Single-lab functional dissection"]},{"year":2003,"claim":"Determined that nyctalopin is a cell-surface protein whose trafficking depends on its N-terminal ER signal sequence and whose plasma membrane retention requires the C-terminal GPI anchor, distinguishing trafficking-disrupting from non-trafficking pathogenic mutations.","evidence":"V5-tagged domain-deletion and mutant constructs expressed in COS-7 and HeLa cells with live-cell vs detergent-extracted immunostaining","pmids":["14507859"],"confidence":"High","gaps":["Heterologous cell lines may not reproduce the retinal trafficking context","Does not identify what nyctalopin binds at the cell surface"]},{"year":2003,"claim":"Localized nyctalopin expression to the inner nuclear and ganglion cell layers across retinal development, placing its function in inner retinal circuitry rather than photoreceptors.","evidence":"RNA in situ hybridization, immunohistochemistry, and RT-PCR in mouse and rat retina","pmids":["12714669"],"confidence":"Medium","gaps":["Layer-level resolution does not assign nyctalopin to specific bipolar cell types or synaptic compartments","Single-lab study"]},{"year":2004,"claim":"Confirmed by pharmacological epistasis that nyctalopin acts principally within the ON-pathway at depolarizing bipolar cells, with no OFF-pathway involvement.","evidence":"ERG in genotyped CSNB1-NYX patients combined with intravitreal APB (ON blocker) and PDA (OFF blocker) in primates across multiple stimulation paradigms","pmids":["15331616"],"confidence":"High","gaps":["Pharmacology localizes the defect to the ON-pathway but does not define nyctalopin's molecular role in mGluR6 signaling complex assembly"]},{"year":2006,"claim":"Used nyx regulatory sequences to mark ON-bipolar cells and revealed how their axon terminals develop, showing filopodial exploration before bouton consolidation as a trial-and-error synaptic targeting mechanism.","evidence":"Transgenic zebrafish expressing membrane-YFP under nyx regulatory sequences with in vivo time-lapse confocal and two-photon imaging","pmids":["17020638"],"confidence":"Medium","gaps":["Reports nyx promoter activity and bipolar cell development, not a direct functional role of the nyctalopin protein in this process","Does not establish whether nyctalopin loss alters axonal targeting"]},{"year":2039,"claim":"Extended the disease mechanism to noncoding NYX variants, showing a 5'UTR/exon 1 variant causes aberrant splicing and reduced nyctalopin, producing a milder phenotype.","evidence":"Whole genome sequencing, in silico splicing prediction, and minigene splicing assay (single case)","pmids":["41729106"],"confidence":"Medium","gaps":["Single case and single lab","Minigene assay does not confirm the splicing outcome or protein reduction in patient retinal tissue"]},{"year":null,"claim":"The molecular partners through which nyctalopin enables ON-bipolar signal transmission and the biochemical step it performs at the cell surface remain undefined.","evidence":"No direct interaction or reconstitution evidence in the available corpus","pmids":[],"confidence":"Low","gaps":["No identified binding partner or substrate","No structural model of the LRR or GPI-anchored protein","Mechanism connecting surface nyctalopin to the depolarizing bipolar signaling cascade is uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,2]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[3,4]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9GZU5","full_name":"Nyctalopin","aliases":[],"length_aa":476,"mass_kda":51.5,"function":"Required for normal vision. Is a critical factor for light-induced depolarization of retinal ON-bipolar cells, likely acting as a scaffold for TRPM1 and GRM6. Required for TRPM1 trafficking to dendritic tips of ON-bipolar cells","subcellular_location":"Secreted, extracellular space, extracellular matrix; Cell projection, dendrite; Postsynapse","url":"https://www.uniprot.org/uniprotkb/Q9GZU5/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NYX","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NYX","total_profiled":1310},"omim":[{"mim_id":"613216","title":"NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1C; CSNB1C","url":"https://www.omim.org/entry/613216"},{"mim_id":"603576","title":"TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY M, MEMBER 1; TRPM1","url":"https://www.omim.org/entry/603576"},{"mim_id":"310500","title":"NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1A; CSNB1A","url":"https://www.omim.org/entry/310500"},{"mim_id":"300278","title":"NYCTALOPIN; NYX","url":"https://www.omim.org/entry/300278"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Not detected","tissue_distribution":"Not detected","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NYX"},"hgnc":{"alias_symbol":["CLRP","CSNB1A"],"prev_symbol":["CSNB1","CSNB4"]},"alphafold":{"accession":"Q9GZU5","domains":[{"cath_id":"3.80.10.10","chopping":"26-161","consensus_level":"medium","plddt":94.5486,"start":26,"end":161},{"cath_id":"3.80.10.10","chopping":"172-337","consensus_level":"medium","plddt":95.1584,"start":172,"end":337},{"cath_id":"-","chopping":"341-390","consensus_level":"medium","plddt":89.3144,"start":341,"end":390}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9GZU5","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9GZU5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9GZU5-F1-predicted_aligned_error_v6.png","plddt_mean":81.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NYX","jax_strain_url":"https://www.jax.org/strain/search?query=NYX"},"sequence":{"accession":"Q9GZU5","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9GZU5.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9GZU5/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9GZU5"}},"corpus_meta":[{"pmid":"11062471","id":"PMC_11062471","title":"Mutations in NYX, encoding the leucine-rich proteoglycan nyctalopin, cause X-linked complete congenital stationary night blindness.","date":"2000","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11062471","citation_count":272,"is_preprint":false},{"pmid":"2574143","id":"PMC_2574143","title":"Assignment of the gene for complete X-linked congenital stationary night blindness (CSNB1) to Xp11.3.","date":"1989","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2574143","citation_count":61,"is_preprint":false},{"pmid":"15331616","id":"PMC_15331616","title":"Primate Retinal Signaling Pathways: Suppressing ON-Pathway Activity in Monkey With Glutamate Analogues Mimics Human CSNB1-NYX Genetic Night Blindness.","date":"2004","source":"Journal of neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/15331616","citation_count":59,"is_preprint":false},{"pmid":"17020638","id":"PMC_17020638","title":"In vivo development of retinal ON-bipolar cell axonal terminals visualized in nyx::MYFP transgenic zebrafish.","date":"2006","source":"Visual neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/17020638","citation_count":52,"is_preprint":false},{"pmid":"17392683","id":"PMC_17392683","title":"Mutations in NYX of individuals with high myopia, but without night blindness.","date":"2007","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/17392683","citation_count":39,"is_preprint":false},{"pmid":"29099938","id":"PMC_29099938","title":"NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory.","date":"2018","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29099938","citation_count":35,"is_preprint":false},{"pmid":"15761389","id":"PMC_15761389","title":"Novel mutations in CACNA1F and NYX in Dutch families with X-linked congenital stationary night blindness.","date":"2005","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/15761389","citation_count":34,"is_preprint":false},{"pmid":"12552565","id":"PMC_12552565","title":"Mutations in the CACNA1F and NYX genes in British CSNBX families.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12552565","citation_count":32,"is_preprint":false},{"pmid":"11581222","id":"PMC_11581222","title":"Slow and fast rod ERG pathways in patients with X-linked complete stationary night blindness carrying mutations in the NYX gene.","date":"2001","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/11581222","citation_count":32,"is_preprint":false},{"pmid":"14507859","id":"PMC_14507859","title":"NYX (nyctalopin on chromosome X), the gene mutated in congenital stationary night blindness, encodes a cell surface protein.","date":"2003","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/14507859","citation_count":29,"is_preprint":false},{"pmid":"23406521","id":"PMC_23406521","title":"A novel missense mutation in the NYX gene associated with high myopia.","date":"2013","source":"Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)","url":"https://pubmed.ncbi.nlm.nih.gov/23406521","citation_count":23,"is_preprint":false},{"pmid":"12714669","id":"PMC_12714669","title":"Isolation of the mouse nyctalopin gene nyx and expression studies in mouse and rat retina.","date":"2003","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/12714669","citation_count":23,"is_preprint":false},{"pmid":"29986951","id":"PMC_29986951","title":"NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain.","date":"2018","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29986951","citation_count":21,"is_preprint":false},{"pmid":"1740347","id":"PMC_1740347","title":"Mapping of locus for X-linked congenital stationary night blindness (CSNB1) proximal to DXS7.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1740347","citation_count":21,"is_preprint":false},{"pmid":"31967361","id":"PMC_31967361","title":"NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model.","date":"2020","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/31967361","citation_count":18,"is_preprint":false},{"pmid":"16670814","id":"PMC_16670814","title":"CSNB1 in Chinese families associated with novel mutations in NYX.","date":"2006","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16670814","citation_count":17,"is_preprint":false},{"pmid":"9418727","id":"PMC_9418727","title":"Localization of CSNBX (CSNB4) between the retinitis pigmentosa loci RP2 and RP3 on proximal Xp.","date":"1997","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/9418727","citation_count":16,"is_preprint":false},{"pmid":"12397430","id":"PMC_12397430","title":"Phenotypic expression of the complete type of X-linked congenital stationary night blindness in patients with different mutations in the NYX gene.","date":"2002","source":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","url":"https://pubmed.ncbi.nlm.nih.gov/12397430","citation_count":16,"is_preprint":false},{"pmid":"25802485","id":"PMC_25802485","title":"NYX mutations in four families with high myopia with or without CSNB1.","date":"2015","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/25802485","citation_count":14,"is_preprint":false},{"pmid":"18617546","id":"PMC_18617546","title":"A common NYX mutation in Flemish patients with X linked CSNB.","date":"2008","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/18617546","citation_count":14,"is_preprint":false},{"pmid":"30242962","id":"PMC_30242962","title":"NYX-2925, A Novel N-methyl-D-aspartate Receptor Modulator: A First-in-Human, Randomized, Double-blind Study of Safety and Pharmacokinetics in Adults.","date":"2018","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/30242962","citation_count":13,"is_preprint":false},{"pmid":"22735794","id":"PMC_22735794","title":"Mutation screening of TRPM1, GRM6, NYX and CACNA1F genes in patients with congenital stationary night blindness.","date":"2012","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22735794","citation_count":10,"is_preprint":false},{"pmid":"24084093","id":"PMC_24084093","title":"Ultrastructural localization of GPR179 and the impact of mutant forms on retinal function in CSNB1 patients and a mouse model.","date":"2013","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24084093","citation_count":10,"is_preprint":false},{"pmid":"21947599","id":"PMC_21947599","title":"An extended 15 Hz ERG protocol (2): data of normal subjects and patients with achromatopsia, CSNB1, and CSNB2.","date":"2011","source":"Documenta ophthalmologica. Advances in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/21947599","citation_count":8,"is_preprint":false},{"pmid":"16348636","id":"PMC_16348636","title":"Anaerobic Production of Extracellular Polysaccharide by Butyrivibrio fibrisolvens nyx.","date":"1992","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16348636","citation_count":8,"is_preprint":false},{"pmid":"31376158","id":"PMC_31376158","title":"NYX-2925 induces metabotropic N-methyl-d-aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor.","date":"2019","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31376158","citation_count":7,"is_preprint":false},{"pmid":"31826698","id":"PMC_31826698","title":"Novel frameshift mutation in NYX gene in a Russian family with complete congenital stationary night blindness.","date":"2019","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31826698","citation_count":6,"is_preprint":false},{"pmid":"15583843","id":"PMC_15583843","title":"Multifocal oscillatory potentials in CSNB1 and CSNB2 type congenital stationary night blindness.","date":"2005","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15583843","citation_count":6,"is_preprint":false},{"pmid":"23289809","id":"PMC_23289809","title":"Electroretinographic findings in a patient with congenital stationary night blindness due to a novel NYX mutation.","date":"2013","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23289809","citation_count":6,"is_preprint":false},{"pmid":"26234941","id":"PMC_26234941","title":"Two Novel NYX Gene Mutations in the Chinese Families with X-linked Congenital Stationary Night Blindness.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26234941","citation_count":6,"is_preprint":false},{"pmid":"25250444","id":"PMC_25250444","title":"Nyx pholeocola, a new genus and cavernicolous species of tribe Aedini (Diptera: Culicidae) from southern Thailand based on morphological and molecular data.","date":"2013","source":"Zootaxa","url":"https://pubmed.ncbi.nlm.nih.gov/25250444","citation_count":5,"is_preprint":false},{"pmid":"33769208","id":"PMC_33769208","title":"Complete congenital stationary night blindness associated with a novel NYX variant (p.Asn216Lys) in middle-aged and older adult patients.","date":"2021","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33769208","citation_count":5,"is_preprint":false},{"pmid":"12124754","id":"PMC_12124754","title":"Cloning of the cDNA and mRNA expression of CLRP, a complex leucine repeat protein of the Golgi apparatus expressed by specific neurons of the rat brain.","date":"2002","source":"Journal of neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/12124754","citation_count":4,"is_preprint":false},{"pmid":"31909296","id":"PMC_31909296","title":"The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC.","date":"2019","source":"Neurobiology of pain (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/31909296","citation_count":4,"is_preprint":false},{"pmid":"35328623","id":"PMC_35328623","title":"Receptive Field Sizes of Nyx Mouse Retinal Ganglion Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35328623","citation_count":1,"is_preprint":false},{"pmid":"41040268","id":"PMC_41040268","title":"The NMDAR positive allosteric modulator NYX-783 selectively blocks opioid withdrawal conditioned place aversion in mice.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41040268","citation_count":1,"is_preprint":false},{"pmid":"30980176","id":"PMC_30980176","title":"[Multimodal diagnostic of CSNB1 with NYX gene mutation].","date":"2019","source":"Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft","url":"https://pubmed.ncbi.nlm.nih.gov/30980176","citation_count":0,"is_preprint":false},{"pmid":"42186038","id":"PMC_42186038","title":"A novel NYX gene mutation identified in a Chinese Northeast Han family with high myopia and night blindness.","date":"2026","source":"BMC ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/42186038","citation_count":0,"is_preprint":false},{"pmid":"41729106","id":"PMC_41729106","title":"Identification and functional validation of a novel disease-causing variant in the noncoding region of NYX.","date":"2026","source":"Acta ophthalmologica","url":"https://pubmed.ncbi.nlm.nih.gov/41729106","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.25.666812","title":"Gene augmentation therapy treats mature mice with complete congenital stationary night blindness (cCSNB), improving retinal function and visual acuity","date":"2025-07-31","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.25.666812","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":22064,"output_tokens":1833,"usd":0.046844,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8780,"output_tokens":2628,"usd":0.0548,"stage2_stop_reason":"end_turn"},"total_usd":0.101644,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"NYX encodes nyctalopin, a GPI-anchored protein and novel member of the small leucine-rich proteoglycan (SLRP) family; mutations in NYX cause X-linked complete congenital stationary night blindness (CSNB1) with ON-pathway defects, implicating nyctalopin in developing retinal interconnections involving ON-bipolar cells.\",\n      \"method\": \"Positional cloning, mutation screening in 22 CSNB1 families, sequence analysis identifying 14 different mutations\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — positional cloning with 14 independent mutations across 22 families, replicated in multiple subsequent independent studies\",\n      \"pmids\": [\"11062471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Human nyctalopin is a cell surface protein; the N-terminal ER signal sequence directs it into the secretory pathway and the C-terminal GPI anchor domain is required for its retention at the plasma membrane. Deletion of the GPI anchor causes accumulation in ER/Golgi and loss from the cell surface. Mouse Nyx also localizes to the cell surface (as speckles), and both require the ER signal sequence for proper intracellular localization. Pathogenic LRR-region mutations do not alter subcellular localization.\",\n      \"method\": \"Expression of V5-tagged wild-type and mutant domain-deletion constructs in COS-7 and HeLa cells; differential live-cell vs. detergent-extracted immunostaining to distinguish surface from intracellular pools\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct localization assay with functional domain deletions and mutagenesis in multiple cell lines, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"14507859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mouse Nyx (nyctalopin) is expressed specifically in the inner nuclear layer and ganglion cell layer of the retina throughout all stages of postnatal retinal development, consistent with a function in the inner retinal circuitry rather than in photoreceptors.\",\n      \"method\": \"RNA in situ hybridization and immunohistochemistry with Nyx-specific antibodies in mouse and rat retina; RT-PCR for tissue distribution\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization by in situ hybridization and immunohistochemistry in two species, single lab\",\n      \"pmids\": [\"12714669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Nyctalopin (NYX) acts principally or exclusively within the ON-pathway at the level of depolarizing (ON) bipolar cells; pharmacological blockade of the ON-pathway in non-human primates with APB fully recreates the ERG abnormalities seen in CSNB1-NYX humans, with no evidence of OFF-pathway involvement.\",\n      \"method\": \"ERG recordings in genotyped CSNB1-NYX human males combined with intravitreal injection of ON-pathway blocker APB and OFF-pathway blocker PDA in anesthetized primates; comparative sinusoidal and ramp-flicker ERG analysis\",\n      \"journal\": \"Journal of neurophysiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological epistasis in primate combined with human genotype-confirmed patient data, replicated across multiple stimulation paradigms\",\n      \"pmids\": [\"15331616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Loss of functional nyctalopin (NYX) abolishes signal transmission through the ON rod bipolar cell (AII amacrine) pathway (slow rod ERG pathway undetectable) but leaves a residual signal via rod-cone gap junctions through the OFF cone pathway (fast rod ERG pathway reduced but present), defining the precise circuit site of nyctalopin action.\",\n      \"method\": \"15-Hz scotopic flicker ERG with amplitude and phase analysis across a range of flash intensities in 11 NYX-mutation-confirmed CSNB1 patients vs. 22 normal controls\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structured ERG dissection of two rod pathways in genotype-confirmed patients, single lab\",\n      \"pmids\": [\"11581222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The upstream regulatory sequences of the nyx gene (zebrafish) drive expression in a subset of ON-bipolar cells; live time-lapse imaging of nyx::MYFP transgenic zebrafish showed that bipolar cell axonal terminals develop through filopodial exploration throughout the IPL before concentrating at discrete foci to form large terminal boutons, establishing a trial-and-error mechanism of synaptic targeting.\",\n      \"method\": \"Transgenic zebrafish expressing membrane-targeted YFP under nyx regulatory sequences; time-lapse confocal and two-photon in vivo imaging of bipolar cell axonal development\",\n      \"journal\": \"Visual neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vivo live imaging in transgenic vertebrate model, single lab, nyx regulatory sequences validate ON-bipolar cell identity\",\n      \"pmids\": [\"17020638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2039,\n      \"finding\": \"A noncoding variant (c.-57G>A) in the 5' UTR/exon 1 of NYX causes aberrant splicing and reduced nyctalopin production, resulting in a milder cCSNB phenotype without high myopia, establishing that noncoding NYX variants can cause disease via a splicing mechanism.\",\n      \"method\": \"Whole genome sequencing, in silico splicing prediction (SpliceAI, Pangolin), minigene splicing assay\",\n      \"journal\": \"Acta ophthalmologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — minigene assay directly demonstrates aberrant splicing, but single case and single lab\",\n      \"pmids\": [\"41729106\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Nyctalopin (NYX) is a GPI-anchored, small leucine-rich proteoglycan that is trafficked via the ER/Golgi to the extracellular face of the plasma membrane of ON-bipolar cells in the inner retina, where it is required for signal transmission through the depolarizing (ON) rod bipolar cell pathway; loss of nyctalopin selectively abolishes ON-pathway signaling while leaving residual transmission through rod-cone gap junctions, and mutations in NYX cause X-linked complete congenital stationary night blindness.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Nyctalopin (NYX) is a GPI-anchored small leucine-rich proteoglycan (SLRP) that is required for signal transmission through the depolarizing (ON) bipolar cell pathway of the inner retina, and its loss causes X-linked complete congenital stationary night blindness (CSNB1) [#0]. The protein is directed into the secretory pathway by an N-terminal ER signal sequence and retained at the extracellular face of the plasma membrane by a C-terminal GPI anchor; deletion of the GPI anchor traps the protein in the ER/Golgi and removes it from the cell surface, whereas pathogenic LRR-region mutations leave localization intact [#1]. Consistent with this circuit role, nyctalopin is expressed in the inner nuclear and ganglion cell layers throughout retinal development rather than in photoreceptors, and zebrafish nyx regulatory sequences mark a subset of ON-bipolar cells [#2, #5]. Functionally, nyctalopin acts at the level of the depolarizing ON-bipolar cells: pharmacological ON-pathway blockade in primates recapitulates the ERG defect seen in NYX-mutant patients, and loss of nyctalopin abolishes transmission through the ON rod bipolar (AII amacrine) pathway while leaving residual signaling via rod-cone gap junctions feeding the OFF cone pathway [#3, #4].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established the gene underlying X-linked complete CSNB and identified its product as a novel GPI-anchored SLRP family member, linking a defined molecule to the long-recognized ON-pathway signaling defect.\",\n      \"evidence\": \"Positional cloning and mutation screening of 22 CSNB1 families identifying 14 distinct mutations\",\n      \"pmids\": [\"11062471\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the subcellular localization or trafficking of the protein\", \"No direct identification of binding partners or the molecular signaling step affected\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved the precise circuit site of nyctalopin action by dissecting which rod pathway is lost, showing the defect is in ON rod bipolar transmission and not in residual rod-cone gap junction routes.\",\n      \"evidence\": \"15-Hz scotopic flicker ERG amplitude/phase analysis in 11 NYX-confirmed patients vs 22 controls\",\n      \"pmids\": [\"11581222\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ERG phenotyping does not reveal the molecular partners or mechanism at the bipolar cell synapse\", \"Single-lab functional dissection\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Determined that nyctalopin is a cell-surface protein whose trafficking depends on its N-terminal ER signal sequence and whose plasma membrane retention requires the C-terminal GPI anchor, distinguishing trafficking-disrupting from non-trafficking pathogenic mutations.\",\n      \"evidence\": \"V5-tagged domain-deletion and mutant constructs expressed in COS-7 and HeLa cells with live-cell vs detergent-extracted immunostaining\",\n      \"pmids\": [\"14507859\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heterologous cell lines may not reproduce the retinal trafficking context\", \"Does not identify what nyctalopin binds at the cell surface\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Localized nyctalopin expression to the inner nuclear and ganglion cell layers across retinal development, placing its function in inner retinal circuitry rather than photoreceptors.\",\n      \"evidence\": \"RNA in situ hybridization, immunohistochemistry, and RT-PCR in mouse and rat retina\",\n      \"pmids\": [\"12714669\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Layer-level resolution does not assign nyctalopin to specific bipolar cell types or synaptic compartments\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Confirmed by pharmacological epistasis that nyctalopin acts principally within the ON-pathway at depolarizing bipolar cells, with no OFF-pathway involvement.\",\n      \"evidence\": \"ERG in genotyped CSNB1-NYX patients combined with intravitreal APB (ON blocker) and PDA (OFF blocker) in primates across multiple stimulation paradigms\",\n      \"pmids\": [\"15331616\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pharmacology localizes the defect to the ON-pathway but does not define nyctalopin's molecular role in mGluR6 signaling complex assembly\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Used nyx regulatory sequences to mark ON-bipolar cells and revealed how their axon terminals develop, showing filopodial exploration before bouton consolidation as a trial-and-error synaptic targeting mechanism.\",\n      \"evidence\": \"Transgenic zebrafish expressing membrane-YFP under nyx regulatory sequences with in vivo time-lapse confocal and two-photon imaging\",\n      \"pmids\": [\"17020638\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reports nyx promoter activity and bipolar cell development, not a direct functional role of the nyctalopin protein in this process\", \"Does not establish whether nyctalopin loss alters axonal targeting\"]\n    },\n    {\n      \"year\": 2039,\n      \"claim\": \"Extended the disease mechanism to noncoding NYX variants, showing a 5'UTR/exon 1 variant causes aberrant splicing and reduced nyctalopin, producing a milder phenotype.\",\n      \"evidence\": \"Whole genome sequencing, in silico splicing prediction, and minigene splicing assay (single case)\",\n      \"pmids\": [\"41729106\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single case and single lab\", \"Minigene assay does not confirm the splicing outcome or protein reduction in patient retinal tissue\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular partners through which nyctalopin enables ON-bipolar signal transmission and the biochemical step it performs at the cell surface remain undefined.\",\n      \"evidence\": \"No direct interaction or reconstitution evidence in the available corpus\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No identified binding partner or substrate\", \"No structural model of the LRR or GPI-anchored protein\", \"Mechanism connecting surface nyctalopin to the depolarizing bipolar signaling cascade is uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [3, 4]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":4,"faith_pct":100.0}}